Feed Top Reports Pricing

⌘K

04:38:40·539d

FDARegulatory

FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

TGTX· TG Therapeutics Inc.

Health Care

Original source

Companies

TGTX
TG Therapeutics Inc.
Health Care

Recent analyst ratings

Oct 6UpdateH.C. Wainwright$60.00
Jul 10UpdateGoldman$37.00
Oct 29UpdateTD Cowen$50.00
Aug 2UpdateGoldman$12.00
Jun 26UpdateJefferies$40.00
May 20UpdateBofA Securities$5.00

Related

PR1d
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
PR8d
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
SEC27d
Amendment: SEC Form SCHEDULE 13G/A filed by TG Therapeutics Inc.
SEC34d
TG Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
PR35d
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
PR48d
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
PR52d
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
SEC55d
SEC Form 10-K filed by TG Therapeutics Inc.

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022